Apogee CFO sells 1,000 APGE shares; remaining holdings 199,871

Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson.

Rhea-AI Filing Summary

Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson. On 11/11/2025, she sold 1,000 shares of common stock at $60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024. Following the sale, she beneficially owns 199,871 shares, held directly.

Insights

Equity markets analyst

Routine Form 4 sale under a 10b5-1 plan; neutral impact.

The CFO of Apogee Therapeutics disclosed a sale of 1,000 shares at $60 on 11/11/2025. The filing notes execution under a Rule 10b5-1 plan adopted on September 27, 2024, which indicates pre-scheduled trades.

After the transaction, the officer reports 199,871 shares beneficially owned, directly. This is a standard insider activity disclosure; actual market impact depends on broader trading volumes and float, which are not provided in the excerpt.

Insider Trade Summary

Net Seller: 1,000 shares

Net Sell 1 txn

Insider Henderson Jane

Role Chief Financial Officer

Sold 1,000 shs ($60K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$60.00	$60K

Holdings After Transaction: Common Stock — 199,871 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

FAQ

What insider trade did APGE disclose on Form 4?

The CFO sold 1,000 shares of common stock at $60 on 11/11/2025.

Who at Apogee Therapeutics (APGE) made the trade?

Chief Financial Officer Jane Pritchett Henderson reported the transaction.

How many APGE shares does the insider hold after the sale?

She beneficially owns 199,871 shares, held directly.

Was the sale under a Rule 10b5-1 plan?

Yes. The trade was executed under a Rule 10b5-1 plan adopted on September 27, 2024.

What was the transaction code on the Form 4?

The filing lists code S for an open-market sale, referenced as S (1) in the table notes.

What is the relationship of the reporting person to APGE?

She is an Officer, serving as Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 08:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		S(1)		1,000	D	$60	199,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.